Drug Approval | December 23, 2025
FDA go-ahead to Roche’s one-minute follicular lymphoma therapy
Full approval will depend on verification of clinical benefit in a confirmatory trial
Full approval will depend on verification of clinical benefit in a confirmatory trial
The drug is designed to improve functional capacity and reduce symptoms by inhibiting cardiac myosin motor activity
This development marks a substantial improvement in the company's financial position and reflects strengthened promoter confidence
NUFYMCO BLA has been approved by the USFDA
Healthcare and insurance are not parallel systems; they are interdependent pillars of patient trust
The company also reported significant progress toward its internally defined Sustainable Development Goals
The MAR-Autism Test represents more than 20 years of research at the UC Davis MIND Institute by Judy Van de Water
The system is intended for some of the tiniest patients—premature infants weighing as little as two pounds
Tablets will be manufactured at Granules' US-based facility located in Chantilly, Virginia
Additional investments planned to expand the site’s capacity and capabilities to support growing manufacturing programs
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
